Keywords: DWI/DTI/DKI, Cancer, Triple-negative breast cancer, Paclitaxel resistance, Mitochondrial dynamics, Inositol, Multiparametric MRI
Motivation: Paclitaxel resistance poses a challenge in treating triple-negative breast cancer (TNBC), necessitating new strategies to enhance treatment efficacy.
Goal(s): The study aims to explore whether inositol can inhibit PTX chemoresistance in TNBC by suppressing mitochondrial fission.
Approach: PTX-resistant 4T1 cells were inoculated in mice, which received treatments with PTX and/or inositol. Multiparametric MRI, histopathology, and biochemical analyses were used to assess effects on mitochondrial morphology and treatment outcomes.
Results: Inositol increased mitochondrial stability, reduced tumor volume, and lowered PTX resistance markers, demonstrating its potential to counteract PTX resistance in TNBC effectively.
Impact: The findings suggest that inositol could become a novel therapeutic strategy for overcoming PTX resistance in TNBC, potentially guiding future research on mitochondrial-targeted treatments. This could lead to improved clinical outcomes for patients with drug-resistant breast cancer.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords